US 12,280,128 B2
Multi-phase oral composition
Jayanth Rajaiah, Loveland, OH (US); Paul Albert Sagel, Mainville, OH (US); and Franco Silva Medeiros, Loveland, OH (US)
Assigned to The Procter & Gamble Company, Cincinnati, OH (US)
Filed by The Procter & Gamble Company, Cincinnati, OH (US)
Filed on Feb. 28, 2022, as Appl. No. 17/682,740.
Application 17/682,740 is a continuation of application No. 15/790,978, filed on Oct. 23, 2017, granted, now 11,259,998.
Claims priority of provisional application 62/413,214, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,237, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,200, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,205, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,189, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,229, filed on Oct. 26, 2016.
Claims priority of provisional application 62/413,222, filed on Oct. 26, 2016.
Prior Publication US 2022/0175633 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61C 19/06 (2006.01); A61K 8/02 (2006.01); A61K 8/06 (2006.01); A61K 8/22 (2006.01); A61K 8/31 (2006.01); A61K 8/34 (2006.01); A61K 8/81 (2006.01); A61K 8/86 (2006.01); A61K 8/92 (2006.01); A61N 5/06 (2006.01); A61Q 11/00 (2006.01); A61Q 11/02 (2006.01)
CPC A61K 8/064 (2013.01) [A61C 19/066 (2013.01); A61K 8/0216 (2013.01); A61K 8/062 (2013.01); A61K 8/22 (2013.01); A61K 8/31 (2013.01); A61K 8/345 (2013.01); A61K 8/8111 (2013.01); A61K 8/86 (2013.01); A61K 8/92 (2013.01); A61N 5/0603 (2013.01); A61N 5/062 (2013.01); A61Q 11/00 (2013.01); A61Q 11/02 (2013.01); A61K 2800/42 (2013.01); A61K 2800/81 (2013.01); A61K 2800/87 (2013.01); A61K 2800/884 (2013.01); A61K 2800/92 (2013.01); A61N 2005/0606 (2013.01); A61N 2005/0663 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A multi-phase oral composition comprising:
a) from about 0.9% to about 40%, by weight of the multi-phase oral composition, of an aqueous phase having a bleaching agent, wherein the amount of the bleaching agent in the multi-phase oral composition is from more than 0.5% to about 20%;
b) a hydrophobic phase comprising from about 50% to about 99.1%, by weight of the multi-phase oral composition, of petrolatum having a drop melting point from about 30° C. to about 90° C. as measured by ASTM D127-08.